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Macrophage pre-treatment with bacterial lipopolysaccharide (LPS) boosts 
subsequent activation of the NLRP3 inflammasome, which controls caspase-1-
dependent pro-inflammatory cytokine maturation. Previous work has attributed 
this phenomenon (known as LPS ‘priming’) to LPS-dependent induction of 
NLRP3 expression. Whilst this plays a role, here we demonstrate that rapid LPS 
priming of NLRP3 inflammasome activation can occur independently of NLRP3 
induction, since the priming effect of LPS is still apparent at short pre-treatment 
times in which NLRP3 protein expression remains unchanged. Furthermore, 
rapid LPS priming is still evident in Nlrp3
-/-
 primary macrophages with NLRP3 
expression reconstituted using a constitutive promoter. Similarly, we found that 
LPS potentiates AIM2 inflammasome activation to submaximal doses of 
cytosolic DNA without concomitant upregulation of AIM2 protein expression. 
Our data suggest that, in addition to augmenting NLRP3 inflammasome activity 
via NLRP3 induction, LPS boosts caspase-1 activation by the NLRP3 and AIM2 
inflammasomes by an acute mechanism that is independent of inflammasome 
sensor induction.  
The innate immune system utilises a suite of receptors to continuously scan the body 
for signs of danger. Such sensors include Nod-like Receptor proteins (e.g. NLRP1, 
NLRP3, NLRC4) and the HIN-200 protein AIM2, which form high molecular weight 
complexes known as “inflammasomes” that control cytokine production as well as 
initiating rapid lytic cell death. Inflammasomes are intracellular sensors for a diverse 
array of danger signals indicative of microbial infection or cellular injury. For 
example, bacterial pore-forming toxins and extracellular ATP released by injured 
cells trigger the NLRP3 inflammasome, whilst cytosolic DNA activates the AIM2 
inflammasome. Activation of the inflammasome sensor component (e.g. NLRP3 or 
AIM2) leads to clustering and proximity-induced activation of the pro-inflammatory 
caspase, caspase-1 (Schroder and Tschopp 2010). For both the NLRP3 and AIM2 
inflammasomes, interaction between the inflammasome sensor component and 
caspase-1 requires a protein adaptor, ASC. Inflammasome target cytokines such as 
interleukin (IL)-1 and IL-18 are expressed within the cell as inactive precursor 
proteins that accumulate intracellularly until the inflammasome pathway is engaged. 
Once activated, caspase-1 converts pro-IL-1 and pro-IL-18 into their active forms 
and directs their non-classical secretion. IL-1 has recently emerged as another 
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inflammasome cytokine target, although it is not directly processed by caspase-1 
(Gross et al. 2012). 
It has long been appreciated that the maturation and secretion of IL-1 triggered by 
the inflammasome requires pre-treatment with a pro-inflammatory stimulus such as a 
toll-like receptor (TLR) agonist (e.g. the TLR4 ligand, bacterial lipopolysaccharide, 
LPS). Pro-IL-1 is not constitutively expressed in most cells, so it was originally 
believed that priming served solely to induce its expression and hence availability as a 
caspase-1 substrate. However, later studies demonstrated that priming also regulates 
the activity of the NLRP3 inflammasome via additional mechanisms upstream of 
substrate availability. For example, caspase-1 activation by the pore-forming toxin 
and NLRP3 agonist, nigericin, absolutely requires pre-treatment with a pro-
inflammatory stimulus such as LPS (Bauernfeind et al. 2009). This phenomenon has 
been attributed to LPS-dependent upregulation of the inflammasome sensor 
component, NLRP3 (Bauernfeind et al. 2009). Here we show that the level of NLRP3 
expression is not the only factor limiting caspase-1 activation, and that LPS may 
augment inflammasome function through additional mechanisms. 
We exposed wild-type bone marrow macrophages (BMM) to the NLRP3 agonists, 
ATP and nigericin, with or without pre-treatment with LPS for various times. In 
keeping with a previous study (Bauernfeind et al. 2009), NLRP3-dependent caspase-1 
activation was highly dependent on prior LPS exposure. In unprimed macrophages, 
caspase-1 activation was at the limit of detection for both ATP and nigericin 
treatment, whereas 6h pre-treatment with LPS potently augmented caspase-1 
activation (Fig. 1A). Interestingly, the timing of LPS priming differentially affected 
caspase-1 activation by ATP compared with caspase-1 activation by nigericin (Fig. 
1A). Priming for 2-20h prior to ATP treatment, or even co-stimulation of cells with 
LPS plus ATP (0h priming), effectively augmented ATP-dependent caspase-1 
activation, whereas strong potentiation of nigericin responses occurred within a 
narrower timeframe (2-6h). This suggests that LPS boosts NLRP3 activation through 
multiple mechanisms that may be differentially engaged by distinct activators. 
Intriguingly, the timeframe within which LPS potentiates caspase-1 activation by 
ATP and nigericin only partially overlaps with that of NLRP3 induction, which peaks 
at 7h post-LPS treatment but remains high until 21h (Fig. 1A). For example, although 
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the 6h and 20h LPS pre-treatments triggered a similar level of NLRP3 protein 
upregulation, 6h LPS was much more effective at promoting nigericin-dependent 
caspase-1 activation. Similarly, co-stimulation of LPS with ATP (0h LPS) boosted 
caspase-1 activation without concurrent upregulation of NLRP3 protein. We thus 
investigated whether NLRP3 upregulation was the only mechanism by which LPS 
promotes NLRP3-dependent caspase-1 activation. We reconstituted NLRP3 
expression by retroviral transduction in Nlrp3-deficient BMM. Despite sustained 
constitutive NLRP3 expression throughout the LPS priming time-course in 
reconstituted primary macrophages, 0-6h LPS pre-treatment still boosted ATP-
dependent caspase-1 activation, and 2-6h LPS pre-treatment augmented caspase-1 
activation by nigericin (Fig. 1B). Since macrophages with constitutive NLRP3 
expression showed caspase-1 cleavage in the absence of LPS treatment (Fig. 1B), 
which was not evident in wild-type cells (Fig. 1A), our data support a role for NLRP3 
induction in contributing to the LPS priming phenomenon. However, other LPS-
dependent mechanisms also boost NLRP3 inflammasome activity over the 0-6h LPS 
pre-treatment time-course. 
We next examined whether LPS modulates the expression of known inflammasome 
pathway members, as such a mechanism may underlie priming at some LPS time-
points. We first characterised the expression of inflammasome components and their 
cytokine targets, and detailed their regulation in multiple human and mouse 
macrophage populations. NLRP3 mRNA was upregulated in BMM, thioglycollate-
elicited peritoneal macrophages (TEPM) and human monocyte-derived macrophages 
(HMDM) (Fig. 1C), in agreement with NLRP3 protein induction in BMM (Fig. 1A). 
NLRC4, another NLR sensor protein that forms a distinct inflammasome, was also 
moderately upregulated by 24h LPS exposure in mouse and human macrophages, 
suggesting LPS priming may also boost NLRC4 inflammasome function (Fig. 1D). 
Another inflammasome sensor protein, AIM2, was substantially upregulated at the 
mRNA level in human macrophages but was only weakly induced in mouse 
macrophages, probably via autocrine type I interferon (Fig. 1E). The inflammasome 
adaptor, ASC was not induced at the mRNA or protein level during the 0-6h window 
when LPS priming was evident, although it was moderately upregulated at 24h at the 
mRNA, but not protein level in murine macrophages (Figs. 1B,F). CASP1 expression 
was induced at 6h in mouse macrophages at the mRNA (Fig. 1G) but not the protein 
5 
level (Fig. 1A.B). In all, these results suggest that LPS priming of NLRP3 
inflammasome activation is unlikely to involve modulation of ASC and caspase-1 
expression levels. LPS is well established to induce the expression of inflammasome 
cytokine substrates, and we characterised the time-course of their inducible 
expression in multiple human and mouse macrophage populations (mRNA for IL-1a, 
IL-1b, and IL-18; Fig. 1H-J).  
Various stress-associated pathways such as reactive oxygen species, K
+
 efflux and 
lysosomal damage are suggested to trigger NLRP3 activity, although the precise 
mechanisms await full characterisation. Both nigericin (directly, due to its pore-
forming properties) and ATP (indirectly, via ligation of the ATP-dependent K
+ 
channel, P2X7R) trigger K
+
 efflux, but the mechanism by which ionic flux might be 
sensed by NLRP3 remains unclear. LPS does not influence the expression of P2x7r 
mRNA in BMM (Schroder et al. 2012), and so this is unlikely to underlie LPS 
priming of ATP responses. We hypothesised that LPS regulation of signalling 
pathways upstream of NLRP3 may also contribute to the priming phenomenon, at 
least for delayed priming effects. NLRP3 activation by ATP and other agonists is 
dependent on reactive oxygen species (ROS), although the precise role of ROS is 
controversial (Bauernfeind et al. 2011; Tschopp and Schroder 2010). ROS derived 
from both mitochondrial respiration and the NADPH oxidase complex have been 
implicated (Tschopp and Schroder 2010). Here, we find that mRNA for two subunits 
of the NADPH oxidase, Cybb and Nox1, are strongly upregulated in mouse 
macrophages, although, interestingly this effect was not apparent in HMDM (Fig. 
1K,L). The nucleotide-binding protein, GBP5, was recently reported to promote 
NLRP3 inflammasome activation by ATP and nigericin (Shenoy et al. 2012), and 
Gbp5 mRNA was substantially upregulated by LPS in mouse and human 
macrophages (Fig. 1M). LPS also regulated signalling molecules required for 
inflammasome activation by agonists other than ATP and nigericin. NLRP3 
inflammasome activation downstream of C-type lectin ligation (e.g. by Candida 
albicans) requires the kinase, SYK, and expression of Syk mRNA was highly induced 
in mouse, but not human macrophages (Fig. 1N). Thus, LPS-dependent upregulation 
of NADPH oxidase-, SYK- and GBP5-dependent pathways may potentiate 
subsequent NLRP3 inflammasome activation by specific agonists. Whilst induction of 
GBP5 and NADPH oxidase subunits may contribute to LPS priming at intermediate 
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time-points (4-6h pre-treatment) they are unlikely to explain rapid LPS priming of 
NLRP3 responses (e.g. 0-2h pretreatment with LPS), as their upregulation by LPS 
occurs after the observed priming effect.  
The observation that even short LPS pre-treatment times effectively boosted NLRP3 
inflammasome activation suggested the existence of an LPS signalling pathway that 
directly influences the ability of the inflammasome complex to form, perhaps via 
post-translational modification or subcellular re-localization of the NLRP3 
inflammasome components, ASC and caspase-1. In order to test this hypothesis, we 
investigated signal integration between LPS and AIM2 inflammasome pathways. 
Unlike NLRP3, which is unlikely to bind directly to its diverse agonists, AIM2 binds 
directly to double-stranded DNA in the cytosol. AIM2 aggregation upon the DNA 
enables ASC-dependent clustering and auto-activation of pro-caspase-1 (Schroder and 
Tschopp 2010). Thus, should LPS signalling regulate the ability of ASC or caspase-1 
to form an inflammasome, caspase-1 activation by the AIM2 inflammasome should 
be boosted by LPS pre-treatment, similar to our observations for NLRP3. Although 
our results support previous studies showing that priming is not absolutely required 
for AIM2 inflammasome activation by high doses of transfected DNA (Bauernfeind 
et al. 2009; Roberts et al. 2009), 4h LPS priming increased the sensitivity of AIM2 to 
submaximal DNA doses (e.g. 5 g) (Fig. 1O). Importantly, AIM2 protein expression 
was not regulated at this timepoint (Fig. 1P). 
Mechanisms by which the TLR and inflammasome pathways intersect are highly 
relevant to inflammation in vivo, because many inflammasome agonists also trigger 
concurrent signalling by TLRs or related pro-inflammatory pathways (e.g. TNF). Our 
data suggest that pro-inflammatory stimuli such as LPS regulate the inflammasome 
pathway at many levels. In addition to transcriptional pathways triggered by LPS that 
upregulate expression of NLRP3, cytokine substrates (IL1/, IL18), and candidate 
signalling molecules upstream of NLRP3 (Fig. 2A), LPS increases the sensitivity or 
activity of the NLRP3 and AIM2 inflammasomes via other, as yet unexplained, 
mechanisms (Fig. 2B). The finding that even very short priming times effectively 
potentiate inflammasome activation (e.g. co-stimulation of LPS plus ATP) suggests 
that TLR4 signalling triggers either post-translational modifications or subcellular re-
localization of proteins required for full inflammasome activation. It is also possible 
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that LPS acutely regulates the expression and/or functions of as yet undefined 
accessory proteins required for optimal inflammasome activation. NLRP3 appeared to 
have more stringent LPS priming requirements than AIM2, suggesting that whilst 
there may be some potentiation of ASC and caspase-1 function shared by both 
pathways, a more critical point of LPS regulation exists upstream of NLRP3. 
In addition to permitting full and timely activation of the AIM2 and NLRP3 
inflammasome pathways, TLR4 co-engagement may also suppress inflammasome-
dependent inflammation at later time-points, by promoting pathways that limit 
inflammasome signalling and effectors. Such candidate LPS-regulated pathways 
include p62-mediated autophagic destruction of NLRP3 (Shi et al. 2012), IFN-
mediated suppression of NLRP1/3 activity and availability of pro-IL-1/ substrates 
(Guarda et al. 2011), and antagonism of the IL-1/ receptor signalling via the 
natural antagonist, IL1RN (Liao et al. 1984), given that mRNA levels of p62, IFNB, 
and IL1RN are all upregulated by LPS (http://macgate.qfab.org) (Schroder et al. 
2012).  
In summary, pro-inflammatory signalling by TLR ligands is likely to regulate the 
inflammasome pathway at multiple levels. As the precise mechanisms directing 
inflammasome sensing and assembly are still unclear, a closer examination of 
mechanisms of signal integration between the TLR and inflammasome pathways may 
yield important insight into the molecular schemes underlying inflammasome 
assembly, activation and deactivation. 
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Figure Legends 
Figure 1. LPS primes the NLRP3 and AIM2 inflammasomes independently of 
inflammasome sensor component expression. Expression of pro-IL-1, pro-
caspase-1, NLRP3, AIM2, and the loading controls GAPDH, tubulin or S6 in cell 
extracts (XT) was detected by western blot. Secretion of mature IL-1 and/or cleaved 
caspase-1 was also examined in cell supernatants (SN). Profiles are representative of 
3 independent replicate experiments. (A) BMM were pre-treated for various times 
with 10ng/ml LPS (L2137 Sigma, or ultrapure, Invivogen) or were left untreated (“-
”), before stimulating with the NLRP3 agonists ATP (5mM, Sigma) or nigericin 
(5M, Sigma) for 1h. (B) The retroviral packaging cell line PlatE was transfected 
with pMSCV empty vector or pMSCV encoding murine Nlrp3. Resulting retrovirus 
was used to transduce Nlrp3
-/-
 bone marrow progenitors during the standard bone 
marrow-derived macrophage differentiation protocol. Transduced BMM were primed 
with LPS or left untreated, then stimulated with ATP or nigericin as for (A). (C-N) 
C57BL/6 mouse bone marrow macrophages (BMM) and thioglycollate-elicited 
peritoneal macrophages (TEPM), as well as human monocyte-derived macrophages 
(HMDM), were prepared and stimulated with 10ng/ml LPS over a time-course (0, 2, 
6, 24h), and mRNA expression was analysed by qPCR as previously described 
(Schroder et al. 2012). Data are mean +/- SEM of 3-4 experiments with cells prepared 
from independent donors/mice. (O) BMM were pre-treated with 10ng/ml LPS or left 
untreated before activating the AIM2 inflammasome via electroporation with 5 or 10 
g DNA as described previously (Roberts et al. 2009), except with incubation of cells 
at 37˚C. (P) BMM were treated for 4h with 10ng/ml LPS or left untreated.  
Figure 2. LPS pre-treatment boosts caspase-1 activation by the NLRP3 and 
AIM2 inflammasomes via multiple mechanisms. (A) LPS signalling boosts 
caspase-1 and cytokine activation by the NLRP3 inflammasome via transcriptional 
regulation of NLRP3, IL-1, IL-1 and IL-18. Upregulation of NOX1, CYBB, GBP5 
and SYK may also contribute to LPS priming of NLRP3 activation by specific 
agonists, as it may enhance reactive oxygen species (ROS, via NOX1 and CYBB), 
NLRP3 co-activator availability (GBP5) or NLRP3-activating C-type lectin signalling 
pathways (SYK). (B) In addition to mechanisms shown in (A), rapid LPS treatment 
also boosts caspase-1 activation by the NLRP3 and AIM2 inflammasomes, via 
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unknown mechanisms that may involve subcellular redistribution or post-translational 
modification of inflammasome components (ASC, caspase-1) or accessory proteins 
that are not currently identified. 
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